Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

RVT-602

- PMLiVE

Takeda makes Crohn’s disease case for subcutaneous Entyvio

Hopes to aid growth

- PMLiVE

$450m diagnostics sale will fuel more Syncona biotech funding

Radiopharmaceuticals firm sold to Braco Imaging

- PMLiVE

Setback for Takeda as Ninlaro flunks amyloidosis trial

Curbs expansion plans for myeloma drug

- PMLiVE

Encouraging early data for Amgen’s BiTE therapies

Including first-in-man data from prostate cancer drug

Brain power: fresh approaches to Alzheimer’s drug discovery

New alliances are learning from past mistakes and breaking down research barriers

- PMLiVE

Takeda’s Entyvio tops Humira in ulcerative colitis

Entyvio is important for post-merger Takeda

Bayer symbol

Bayer, Orion prep challenge in prostate cancer market

New arrival will face tough competition, not least generic Zytiga

- PMLiVE

Merck puts prostate cancer firmly in Keytruda’s sights

Lynparza combination could open up huge new market

- PMLiVE

J&J’s Erleada cleared for early prostate cancer in Europe

Signals competiton for Xtandi

- PMLiVE

Shire bags US approval for constipation drug Motegrity

Approval is boost as Takeda takeover nears completion

- PMLiVE

Takeda secures investor backing for £46bn Shire takeover

The deal is expected to close early next year

- PMLiVE

Generic threat looms to J&J’s blockbuster Zytiga in US

Impact could also be felt by Pfizer

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links